New York, June 3, 2026, 11:20 EDT
MacroGenics Inc. shares moved higher Wednesday in late-morning trading on the Nasdaq. The stock outperformed other biotech names as investors circled back to the cancer-drug developer, with its cash position and clinical-data timeline getting new attention.
The stock last traded at $4.22, putting it up 4.1% on the day after moving between $4.05 and $4.25. Market cap was about $267 million. The SPDR S&P Biotech ETF ticked up 0.6% and the iShares Nasdaq Biotechnology ETF matched that gain. Both ETFs track baskets of biotech stocks.
The move caught some attention with the broader U.S. market trending lower. According to Reuters, Wall Street’s major indexes traded down as oil climbed following new Middle East tensions, prompting investors to pull back from recent highs. Alexander Lis, chief investment officer at Social Discovery Ventures, told Reuters that traders would likely wait for “solid evidence” of inflation pressure before pushing U.S. stocks much lower. Reuters
MacroGenics shares have bounced around in May. The stock finished at $2.95 on May 11, jumped to $4.25 by May 15, then edged down to $4.16 on May 29, company filings show. Wednesday’s gain is less a breakout than another look at the same rally.
Runway remains the main concern. In a May 13 filing, MacroGenics laid out plans to boost cash, saying its manufacturing sale and broadened ZYNYZ royalty deals should bring in as much as $202.5 million combined, with $122.5 million tied to Bora and $60 million already in from Sagard. CEO Eric Risser said these moves aim to “sharpen our focus” and “strengthen our financial position.” SEC
Time is cash for a biotech still in the clinic. MacroGenics said it expects its pile of cash, marketable securities, incoming partner money, and Bora deal proceeds to last into 2028. That should give the company enough time to test its cancer drugs and report results before any new financing worries crop up.
MacroGenics is lining up drug data readouts. The company expects to report initial Phase 1 results for its ADC MGC026 by mid-2026, and then initial data for MGC028 in the back half of that year. MacroGenics is also aiming to file an IND for MGC030 in the third quarter, which would start U.S. human trials.
Not much on the company schedule explains the move. MacroGenics’ investor page archived the May 20 Stifel 2026 Virtual Targeted Oncology Forum and does not show any events coming up. Price moves look more linked to positioning, liquidity, and the clinical timeline than to any new news from the company.
MacroGenics’ balance sheet gives part of the picture. The company posted a net loss of $36.8 million for the first quarter, on revenue of $20.8 million. R&D expenses hit $35.0 million. As of March 31, cash and marketable securities stood at $154.2 million. That figure doesn’t count the $60 million from Sagard, which arrived after the quarter ended.
Peers were mixed. ADC Therapeutics dropped 2.1%. Zymeworks, which works with antibody-based and ADC tech, gained 0.9%. The comparison isn’t perfect, and it suggests MacroGenics wasn’t just tracking one simple ADC move.
The trade could also go against them. The Bora payout is tied to closing conditions, and the clinical work is still early. Lorigerlimab faces safety and efficacy questions. MacroGenics reported that 47% of evaluable clear-cell gynecologic cancer patients at one dose level had Grade 3 or worse treatment-related side effects—serious or medically significant. The company dropped plans for a platinum-resistant ovarian cancer group after not meeting a response bar.
MacroGenics shares are up today as investors look at cash on hand, timelines, and wait for more trial results. The clinic still has the real answer.
